Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

5.4K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.4K
Loss of Tumor Suppressor Gene Functions01:12

Loss of Tumor Suppressor Gene Functions

6.2K
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
6.2K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

10.0K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
10.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mutational signatures of environmental carcinogens in human tissue organoids revealed by duplex sequencing.

Cell reports·2026
Same author

<sup>32</sup>P-Postlabeling Analysis of DNA Adducts.

Methods in molecular biology (Clifton, N.J.)·2025
Same author

Organoids for Genotoxicity Assessment.

Methods in molecular biology (Clifton, N.J.)·2025
Same author

IARC Workshop on the Key Characteristics of Carcinogens: Assessment of End Points for Evaluating Mechanistic Evidence of Carcinogenic Hazards.

Environmental health perspectives·2025
Same author

Implementing Mutational Epidemiology on a Global Scale: Lessons from Mutographs.

Cancer discovery·2025
Same author

Genome-modified Caenorhabditis elegans expressing the human cytochrome P450 (CYP1A1 and CYP1A2) pathway: An experimental model for environmental carcinogenesis and pharmacological research.

Environment international·2024

Related Experiment Video

Updated: Mar 12, 2026

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

25.2K

Nutlin-3a selects for cells harbouring TP53 mutations.

Jill E Kucab1, Monica Hollstein2,3, Volker M Arlt1

  • 1King's College London, Analytical and Environmental Sciences Division, MRC-PHE Centre for Environment & Health, London, United Kingdom.

International Journal of Cancer
|November 5, 2016
PubMed
Summary
This summary is machine-generated.

Nutlin-3a, an MDM2 inhibitor, effectively distinguishes TP53-mutated cells from wild-type cells in the human TP53 knock-in immortalisation assay. This improves the efficiency of identifying TP53 mutations in cancer research.

Keywords:
HupkiNutlin-3aTP53immortalisationmutation

More Related Videos

Establishing Cell Lines Overexpressing DR3 to Assess the Apoptotic Response to Anti-mitotic Therapeutics
12:28

Establishing Cell Lines Overexpressing DR3 to Assess the Apoptotic Response to Anti-mitotic Therapeutics

Published on: January 11, 2019

7.8K
Yeast As a Chassis for Developing Functional Assays to Study Human P53
14:57

Yeast As a Chassis for Developing Functional Assays to Study Human P53

Published on: August 4, 2019

10.1K

Related Experiment Videos

Last Updated: Mar 12, 2026

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

25.2K
Establishing Cell Lines Overexpressing DR3 to Assess the Apoptotic Response to Anti-mitotic Therapeutics
12:28

Establishing Cell Lines Overexpressing DR3 to Assess the Apoptotic Response to Anti-mitotic Therapeutics

Published on: January 11, 2019

7.8K
Yeast As a Chassis for Developing Functional Assays to Study Human P53
14:57

Yeast As a Chassis for Developing Functional Assays to Study Human P53

Published on: August 4, 2019

10.1K

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • TP53 mutations are prevalent in human cancers, necessitating reliable methods for studying mutagenesis.
  • The human TP53 knock-in immortalisation assay (HIMA) is used to study TP53 mutagenesis but requires lengthy TP53 sequencing.
  • Wild-type TP53 (TP53-WT) cultures require extensive maintenance during the HIMA.

Purpose of the Study:

  • To enhance the selectivity of the HIMA for identifying TP53 mutations.
  • To evaluate Nutlin-3a, an MDM2 inhibitor, as a tool to discriminate between TP53-WT and TP53-mutated cells.
  • To improve the efficiency of TP53 mutation screening in cell culture models.

Main Methods:

  • Human TP53 knock-in (Hupki) mouse embryo fibroblast (HUF) cell lines with wild-type or mutated TP53 were treated with Nutlin-3a.
  • The effect of Nutlin-3a on cell growth and p53 activation was assessed in established immortalized HUF lines.
  • Nutlin-3a sensitivity/resistance was evaluated in emerging immortal clones during the HIMA, followed by TP53 sequencing.

Main Results:

  • Nutlin-3a activated the p53 pathway and inhibited growth in TP53-WT HUFs, while TP53-mutated HUFs showed resistance.
  • In the HIMA, Nutlin-3a-resistant clones consistently harbored diverse TP53 mutations.
  • Nutlin-3a-sensitive clones were predominantly TP53-WT, with only one exception.

Conclusions:

  • Incorporating a Nutlin-3a counter-screen significantly improves the specificity and efficiency of the HIMA.
  • This approach allows for the selection of TP53-mutated clones before sequencing, reducing effort.
  • TP53-WT clones can be efficiently discarded, streamlining cancer mutation studies.